Therapy Directory

Pembrolizumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention. Browse Pembrolizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1844

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
Interventions: Laboratory Biomarker Analysis, Lenalidomide, Pembrolizumab, Rituximab; Other · Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Interventions: Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography; Procedure · Radiation · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 342
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 264 more

Conditions: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab; Drug
Lead sponsor: Aminex Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more

Conditions: Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
Interventions: Quemliclustat, Biospecimen Collection, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Biopsy Procedure; Drug · Procedure · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Questionnaire Administration; Drug · Procedure · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 70 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 327
States / cities: Fayetteville, Arkansas • Fort Smith, Arkansas • Rogers, Arkansas + 257 more

Conditions: Cancer
Interventions: Atezolizumab, Bevacizumab, Alectinib, Cobimetinib, Vemurafenib, FAP IL2V, Venetoclax, Enzalutamide, Pembrolizumab, Sunitinib, Niraparib, Cabozantinib, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 7
States / cities: Aurora, Colorado • Trumbull, Connecticut • Boston, Massachusetts + 3 more

Conditions: High Grade Meningioma
Interventions: Pembrolizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumors, Colorectal Cancer
Interventions: VVD-133214, Pembrolizumab, Bevacizumab; Drug
Lead sponsor: Vividion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 18
States / cities: Tucson, Arizona • Duarte, California • Irvine, California + 14 more

Conditions: NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
Interventions: Pembrolizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 10
States / cities: Stanford, California • Basking Ridge, New Jersey • Hackensack, New Jersey + 7 more

Conditions: Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid Carcinoma
Interventions: Dabrafenib, Trametinib, Pembrolizumab, Pulsed Stereotactic Ablative Radiotherapy, Ethos; Drug · Biological · Radiation + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ovarian Cancer Recurrent
Interventions: Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication, Pembrolizumab, Gemcitabine, Pegylated liposomal doxorubicin, MK-2010; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 10
States / cities: New Haven, Connecticut • Louisville, Kentucky • Shreveport, Louisiana + 7 more

Conditions: Advanced Or Metastatic Merkel Cell Carcinoma
Interventions: IFx-Hu2.0, Pembrolizumab; Drug
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Tampa, Florida • Madison, Wisconsin

About this Pembrolizumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pembrolizumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Pembrolizumab clinical trials

Filter and sort this therapy

Live official records

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

About this Pembrolizumab clinical trials directory page